Pfizer
Pfizer Inc., a leading global biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1849. With a strong presence in North America, Europe, and Asia, Pfizer operates across various sectors, including vaccines, oncology, and rare diseases. The company is renowned for its core products, such as the COVID-19 vaccine and groundbreaking cancer therapies, which leverage advanced biotechnology to address unmet medical needs. Pfizer's commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. With a robust portfolio and a reputation for quality, Pfizer continues to shape the future of healthcare, making a profound impact on global health outcomes.
DitchCarbon Score
How does Pfizer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pfizer's score of 77 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pfizer's reported carbon emissions
In 2022, Pfizer reported total greenhouse gas emissions of approximately 1,097,707,000 kg CO2e, comprising 620,124,000 kg CO2e from Scope 1 and 486,384,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 46% from a 2019 baseline by 2030. Additionally, Pfizer is committed to achieving net-zero emissions by 2040, targeting a 95% reduction in its direct emissions and a 90% reduction in its value chain emissions from 2019 levels. Pfizer's near-term targets include a 25% reduction in Scope 3 emissions from business travel by 2025 and a 10% reduction in Scope 3 emissions from upstream transportation and distribution by the same year. Furthermore, the company aims for 64% of its suppliers, by spend, to have science-based targets by 2025. These initiatives reflect Pfizer's commitment to sustainability and its proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
